Summary
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland.
Documents
- NICE HST 1 - Eculizumab for Treating Atypical Haemolytic Uraemic Syndrome - Section 75 Questionnaire
- NICE HST 1 - Eculizumab for Treating Atypical Haemolytic Uraemic Syndrome - Section 75 Questionnaire
Consultation description
On 1 July 2006 the Department established links with NICE whereby all technology appraisals and clinical guidelines published from that date are locally reviewed for applicability to Northern Ireland and, where appropriate, are endorsed for implementation in health and social care. THE LOCAL REVIEW DOES NOT REASSESS THE CLINICAL AND COST EVIDENCE USED BY NICE IN FORMING ITS ADVICE. This link has ensured that Northern Ireland has access to up-to-date, independent, professional, evidence-based guidance on the value of health care interventions.
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS. The NICE highly specialised technologies programme only considers drugs for very rare conditions. The Department recently agreed to consider NICE HST evaluations in the same way as the process set out for Technology Appraisals.
Guidance for the consultation can be found on the NICE website.
The HSC (SQSD) 2/13 circular provides details of the process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.
We are in the process of updating this circular to reflect the inclusion of HSTs and will advise you when this is complete but for the meantime the process as set out in the circular will be followed for HSTs as for TAs.
In order to meet the timescales set out in the circular, the closing date for responses is Monday 18th July 2016.
This will inform the Equality Screening
Ways to respond
Consultation closed — responses are no longer being accepted.